403 related articles for article (PubMed ID: 15581210)
1. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
[TBL] [Abstract][Full Text] [Related]
2. Multidrug-resistant tuberculosis management in resource-limited settings.
Nathanson E; Lambregts-van Weezenbeek C; Rich ML; Gupta R; Bayona J; Blöndal K; Caminero JA; Cegielski JP; Danilovits M; Espinal MA; Hollo V; Jaramillo E; Leimane V; Mitnick CD; Mukherjee JS; Nunn P; Pasechnikov A; Tupasi T; Wells C; Raviglione MC
Emerg Infect Dis; 2006 Sep; 12(9):1389-97. PubMed ID: 17073088
[TBL] [Abstract][Full Text] [Related]
3. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.
Gammino VM; Taylor AB; Rich ML; Bayona J; Becerra MC; Bonilla C; Gelmanova I; Hollo V; Jaramillo E; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riektsina V; Tupasi TE; Wells CD; Zignol M; Cegielski PJ
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1315-22. PubMed ID: 22283887
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Yedilbayev A; Rich ML; Mukherjee JS; Furin JJ; Atwood S; Farmer PE; Keshavjee S
Int J Tuberc Lung Dis; 2007 Dec; 11(12):1314-20. PubMed ID: 18034952
[TBL] [Abstract][Full Text] [Related]
5. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
[TBL] [Abstract][Full Text] [Related]
6. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
[TBL] [Abstract][Full Text] [Related]
8. Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines.
Gler MT; Guilatco RS; Guray CV; Tupasi TE
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1326-30. PubMed ID: 22863522
[TBL] [Abstract][Full Text] [Related]
9. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus.
Ollé-Goig JE; Sandy R
Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis.
Furin JJ; Mitnick CD; Shin SS; Bayona J; Becerra MC; Singler JM; Alcantara F; Castañieda C; Sanchez E; Acha J; Farmer PE; Kim JY
Int J Tuberc Lung Dis; 2001 Jul; 5(7):648-55. PubMed ID: 11467371
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes.
Leimane V; Leimans J
Euro Surveill; 2006; 11(3):29-33. PubMed ID: 16567876
[TBL] [Abstract][Full Text] [Related]
13. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.
Kurbatova EV; Gammino VM; Bayona J; Becerra M; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1553-5, i. PubMed ID: 22008772
[TBL] [Abstract][Full Text] [Related]
14. Multidrug-resistant tuberculosis among previously treated patients in the Philippines.
Gler MT; Macalintal LE; Raymond L; Guilatco R; Quelapio MI; Tupasi TE
Int J Tuberc Lung Dis; 2011 May; 15(5):652-6. PubMed ID: 21756517
[TBL] [Abstract][Full Text] [Related]
15. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
Mitnick C; Bayona J; Palacios E; Shin S; Furin J; Alcántara F; Sánchez E; Sarria M; Becerra M; Fawzi MC; Kapiga S; Neuberg D; Maguire JH; Kim JY; Farmer P
N Engl J Med; 2003 Jan; 348(2):119-28. PubMed ID: 12519922
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines.
Ohkado A; Aguiman L; Adlawan S; Baring E; Quirante O; Suchi M; Endo S; Fujiki A; Mori T
Int J Tuberc Lung Dis; 2006 Mar; 10(3):283-9. PubMed ID: 16562708
[TBL] [Abstract][Full Text] [Related]
17. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].
Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M
Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681
[TBL] [Abstract][Full Text] [Related]
18. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru.
Mukherjee JS; Joseph JK; Rich ML; Shin SS; Furin JJ; Seung KJ; Sloutsky A; Socci AR; Vanderwarker C; Vasquez L; Palacios E; Guerra D; Viru FA; Farmer P; Del Castillo HE
Int J Tuberc Lung Dis; 2003 Jul; 7(7):637-44. PubMed ID: 12870684
[TBL] [Abstract][Full Text] [Related]
19. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.
Kurbatova EV; Taylor A; Gammino VM; Bayona J; Becerra M; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Viiklepp P; Zignol M; Cegielski JP
Tuberculosis (Edinb); 2012 Sep; 92(5):397-403. PubMed ID: 22789497
[TBL] [Abstract][Full Text] [Related]
20. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
